Vaccination of C57BL/10 Mice against Cutaneous Leishmaniasis. Use of Purified gp63 Encapsulated into Niosomes Surfactants Vesicles: A Novel Approach

DNA vaccines induce partial protection against Leishmania mexicana

“…Purified or recombinant antigens such as GP63, cysteine proteinase (CP) b and GP46/M-2 can induce significant protection against L. mexicana or its close relative L. amazonensis [10,[20][21][22]. However, as in the case of L. major, the efficacy of these vaccine candidates is still partial, and DNA vaccines may be able to induce a better immunity than recombinant vaccines.…”

Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin (Case Report)

“…Polysorbates and similar compounds have been utilized as adjuvants in vaccine research 16–20 . These substances are used in the manufacture of niosomes (‘non‐ionic liposomes’), also known as non‐ionic surfactant vesicles (NISV).…”

“…Polysorbates and similar compounds have been utilized as adjuvants in vaccine research. [16][17][18][19][20] These substances are used in the manufacture of niosomes ('nonionic liposomes'), also known as non-ionic surfactant vesicles (NISV). These consist of a synthetic non-ionic surfactant made from a number of organic compounds including fatty acids, fatty esters, amides, ethers, diethanolamides, polyoxypropylene, polysorbates and phospholipids encapsulating a core containing the immunogen in an aqueous solution.…”

Crossing Biological Barriers for Leishmaniasis Therapy: From Nanomedicinal Targeting Perspective

“…Niosomes have also found their role in vaccination against leishmaniasis. Purified gp63 entrapped into niosomal formulation provided considerable resistance to the leishmaniasis when used as the subcutaneous vaccine in C57BL/10 mice [58].…”